Idorsia, Still Facing Cash Crunch, Says Cost-Reduction Effort Will Conclude In 2023
With a commercial product ramping up in the US and EU and three Phase III candidates, Idorsia is burning through cash quickly and needs more remedies beyond its 475-person headcount reduction.
